Geïncludeerd in de RATE-study

RATE

Reduced Anticoagulation Targets in Extracorporeal life support

Antistollingstarget tijdens ECMO:

- **<u>2.0-2.5x baseline aPTT (60-75 seconden)</u>**

Voor crossover flowchart z.o.z.


Start ECMO
Start heparin
(may be postponed, e.g. in bleeding post-cardiac surgery patient)
Enrolment and randomization
1.5-2.0x baseline aPTT (about 45-60 sec)
2-2.5x baseline aPTT (about 60-75 sec)
LMWH
Therapeutic dose guided by weight and renal function
Thromboembolic event (primary endpoint met) or acquired vital indication for high therapeutic anticoagulation
Severe bleeding or thromboembolic event (primary endpoint met)
Anti-fXa peak level
(not mandatory)
>1.0 (twice daily dosing)
Or:
≥2 ECMO exchanges due to clots and additional laboratory results that point towards a strong risk for hy-
Or:
Bleeding requiring 1-3 PRBC/day and additional laboratory results that point towards a strong risk
Or:
Bleeding requiring 1-3 PRBC/day and additional laboratory results that point towards a strong risk for
Switch temporary to higher anticoagulation level or LMWH
Switch temporary to lower anticoagulation level or temporary withhold heparin
Temporary withhold LMWH or reduce LMWH dose or switch temporary to heparin